Company intelligence / Profile preview

Micelle Labs

West Palm Beach, Florida, United States

Ownership: Private
Development stage: Other

Overview

Micelle BioPharma's ALT-formulated hormone replacement therapies have reached Phase 3 development. Other programs are in preclinical or earlier stages, including SC-410 for nonalcoholic steatohepatitis (discovery stage) and SC-412 for retinitis pigmentosa (pending status). The company previously pursued docosahexaenoic acid for hypertriglyceridemia, now discontinued.[5]

Therapeutic areas: EndocrinologyOphthalmologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Micelle Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micelle Labs.

Explore the full profile